The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $117.65

Today's change-1.93 -1.61%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $117.65

Today's change-1.93 -1.61%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Celgene Corp crosses below 200-day moving average

Celgene Corp closed sharply lower Thursday, dropping (U.S.)$1.93 or 1.61% to (U.S.)$117.65 and crossing below its 200-day moving average. Shares have lost 4.38% over the last five days, but have gained 5.18% over the last year to date. This security has outperformed the S&P 500 by 26.40% during the last year.

Key company metrics

  • Open(U.S.) $120.08
  • Previous close(U.S.) $119.58
  • High(U.S.) $121.14
  • Low(U.S.) $117.09
  • Bid / Ask(U.S.) $117.10 / (U.S.) $117.75
  • YTD % change+5.18%
  • Volume3,677,279
  • Average volume (10-day)7,068,581
  • Average volume (1-month)5,033,880
  • Average volume (3-month)4,900,031
  • 52-week range(U.S.) $83.16 to (U.S.) $140.72
  • Beta1.01
  • Trailing P/E44.57×
  • P/E 1 year forward25.02×
  • Forward PEG1.00×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.64
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+26.08%

Based on its net profit margin of 26.08%, Celgene Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.38%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue2,2782,0812,0861,982
Total other revenue--------
Total revenue2,2782,0812,0861,982
Gross profit2,1771,9771,9821,885
Total cost of revenue10110410398
Total operating expense1,8651,2241,3341,338
Selling / general / administrative617529544498
Research & development1,110506585675
Depreciation / amortization64646464
Interest expense (income), net operating--------
Unusual expense (income)-2621384
Other operating expenses, total--------
Operating income412857752645
Interest income (expense), net non-operating-64-63-64-64
Gain (loss) on sale of assets--------
Other--------
Income before tax471827711578
Income after tax356719614509
Income tax, total1151089769
Net income356719614509
Total adjustments to net income--------
Net income before extra. items356719614509
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items356719614509
Inc. avail. to common incl. extra. items356719614509
Diluted net income356719614509
Dilution adjustment--------
Diluted weighted average shares825834835833
Diluted EPS excluding extraordinary itemsvalue per share0.430.860.740.61
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share0.410.880.770.61